The field of cell and gene therapy (CGT) has made remarkable strides in recent years, offering new hope to patients across an increasingly wide range of conditions. However, the field’s growth has ...
The first vector-delivered gene therapies to receive FDA approval for clinical use were Luxturna,1 Spark Therapeutics’ vision loss cure, and Zolgensma,2 Novartis’ spinal muscular atrophy treatment.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) today announced expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a ...
Researchers have developed a new methodology that uses artificial intelligence (AI) tools to identify and count target viruses more efficiently than ...
LumaCyte today announced that its analytical approach has been included in the newly published International Organization for Standardization (ISO) global standard for gene delivery systems, ISO 16921 ...
High-throughput virology, design of experiments, and small-molecule production enhancers optimize yield and increase ...
Advances company’s ambition to provide fully integrated and comprehensive solution for viral vector manufacturing Mirus Bio’s leading GMP transfection reagents complement company’s upstream ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results